The present invention relates to the use of a substance selected from the group consisting of avermectins and milbemycins, particularly the substance ivermectin, for preparing an antiviral medicament for the treatment of a Flavivirus infection, preferably an infection caused by YFV (yellow fever virus), DENV (Dengue virus), JEV (Japanese encephalitis virus), TBEV (tick-borne encephalitis virus) or MODV (Modoc virus). The antiviral medicament of the present invention is suitable for oral administration to a Flavivirus-infected subject, such as a human being or other mammal.
The present invention relates to a novel therapeutic application of avermectins and milbemycins.

The avermectins are a series of eight macrocyclic lactones ("macrolides") having a broad spectrum antiparasitic activity. These compounds, also designated as the "C-076 complex", are produced by the soil microorganism *Streptomyces avermitilis*. The isolation and chemical structure of the eight individual components of the C-076 complex is disclosed e.g. in GB 1573955, which is herein incorporated by reference. Selective hydrogenation products of the C-076 compounds and derivatives thereof are disclosed in US 4199569.

The milbemycins are a group of antiparasite macrolides structurally related to the C-076 complex, distinguished from the avermectins in that they lack the sugar residue attached at the C-13 position. Examples of such compounds are disclosed e.g. in GB 1390336, EP 170006, EP 254583, EP 334484 and EP 410615.

Ivermectin falls within the group of avermectins. This substance consists of a mixture of 80% or more of avermectin B₁₅ and 20% or less of avermectin Bib. The structural formula of avermectin B₁₅ and avermectin B₁₅ is illustrated below:
Avermectin Bi₂: R = C₂H₅; Avermectin Bi₃: R = CH₃.

Ivermectin is a semi synthetic, anti-helmintic agent suitable for oral administration. In the mid 1980’s, this active ingredient was introduced on the market as probably the broadest-spectrum anti-parasite medication ever. Traditionally it was used against worms (except tapeworms), but more recently it has been found to be effective against most mites and some lice as well. It is sold under the trademark names Stromectol in the United States, Mectizan in Canada by Merck, and Ivexterm in Mexico by Valeant Pharmaceuticals International. Mectizan is currently used to help eliminate river blindness (onchocerciasis) and stop transmission of lymphatic filariasis. Ivermectin kills the parasite by interfering with the nervous system and muscle function, in particular by enhancing inhibitory neurotransmission. The drug binds and activates glutamate-gated chloride channels (GluCls) present in neurons and myocytes. The main concern in connection with the administration of ivermectin is its neurotoxicity, which in most mammalian species can give rise to CNS depression and ataxia, as might be expected from potentiating inhibitory GABA-ergic synapses. Ivermectin is mainly used in humans in the treatment of onchocerciasis, but it is also effective against other worm infestations, such as strongyloidiasis, ascariasis, trichuriasis and enterobiasis. More recent evidence supports its off-label use in the treatment of mites such as scabies, usually limited to cases that prove resistant to topical treatments and/or which are in an advanced state, such as Norwegian scabies.

The present inventors have now surprisingly found that ivermectin is capable of inhibiting the enzymatic activity of Flavivirus helicase, an enzyme required for the replication of Flaviviruses.

Flaviviruses are a genus of ssRNA positive-strand viruses belonging to the Flaviviridae family. Most Flaviviruses are arthropod-borne viruses (Arboviruses), transmitted either by ticks (tick born viruses, TBV) or by mosquitoes (mosquito borne viruses, MBV), but a number of Flaviviruses have no known vector (NKV) and/or have been isolated from infected animals without a known relation to a specific disease.
The genus Flavivirus consists of a number of different species. A list of the currently known Flavivirus species, downloaded from the NCBI Taxonomy Browser (http://www.ncbi.nlm.nih.gov/Taxonomy/Browser), is provided herein below by way of illustration:

- **Aroa virus**
  - Bussuquara virus
  - Iguape virus
  - Naranjal virus

- **Dengue virus group**
  - Dengue virus
    - Dengue virus 1
    - Dengue virus 2
    - Dengue virus 3
    - Dengue virus 4

- **Japanese encephalitis virus group**
  - Japanese encephalitis virus
    - Japanese encephalitis virus strain JAOARS982
    - Japanese encephalitis virus strain Nakayama
    - Japanese encephalitis virus strain SA(V)
    - Japanese encephalitis virus strain SA-14
  - Koutango virus
  - Murray Valley encephalitis virus
    - Alfuy virus
    - Murray valley encephalitis virus (strain MVE-1-51)

- **St. Louis encephalitis virus**
  - St. Louis encephalitis virus (strain MS1-7)

- **Usutu virus**

- **West Nile virus**
  - Kunjin virus
  - West Nile virus crow/New York/3356/2000
  - West Nile virus H442
  - West Nile virus SA381/00
- West Nile virus SA93/01
- West Nile virus SPU1 16/89
- West Nile virus strain 385-99
- West Nile virus strain PT5.2
- West Nile virus strain PT6.16
- West Nile virus strain PT6.39
- West Nile virus strain PT6.5
- West Nile virus strain PTRoxo
  - Kokobera virus group
    - Kokobera virus
      - New Mapoon virus
      - Stratford virus
    - unclassified Kokobera virus group
      - CY1014 virus
  - Modoc virus group
    - Cowbone Ridge virus
    - Jutiapa virus
    - Modoc virus
    - Sal Vieja virus
    - San Perlita virus
  - mosquito-borne viruses
    - Ilheus virus
      - Rocio virus
      - Sepik virus
  - Ntaya virus group
    - Bagaza virus
    - Israel turkey meningoencephalomyelitis virus
    - Ntaya virus
  - Tembusu virus
    - Sitiawan virus
    - Yokose virus
  - Rio Bravo virus group
• Apoi virus
• Bukalasa bat virus
• Carey Island virus
• Dakar bat virus
• Entebbe bat virus
• Rio Bravo virus
  o Saboya virus
    ▪ Potiskum virus
  o Seaborne tick-borne virus group
    ▪ Meaban virus
    ▪ Saumarez Reef virus
    ▪ Tyuleniy virus
  o Spondweni virus group
    ▪ Zika virus
      ▪ Spondweni virus
  o tick-borne encephalitis virus group
    ▪ Kyasanur forest disease virus
      ▪ Alkhurma hemorrhagic fever virus
    o Langat virus
      ▪ Langat virus (strain TP21)
      ▪ Langat virus (strain Yelantsev)
  o Louping ill virus
    ▪ Louping ill virus (strain 31)
    ▪ Louping ill virus (strain K)
    ▪ Louping ill virus (strain Negishi 3248/49/P10)
    ▪ Louping ill virus (strain Norway)
    ▪ Louping ill virus (strain SB 526)
• Omsk hemorrhagic fever virus
• Phnom Penh bat virus
  o Powassan virus
    ▪ Deer tick virus
    ▪ Tick-borne powassan virus (strain lb)
Royal Farm virus
  • Karshi virus

Tick-borne encephalitis virus
  • Kumlinge virus
  • Negishi virus
  • Tick-borne encephalitis virus (strain HYPR)
  • Tick-borne encephalitis virus (STRAIN SOFJIN)
  • Tick-borne encephalitis virus (WESTERN SUBTYPE)
  • Turkish sheep encephalitis virus

Yaounde virus

Yellow fever virus group
  • Banzi virus
  • Boubouï virus
  • Edge Hill virus
  • Uganda S virus
  • Wesselsbron virus

Yellow fever virus
  • Yellow fever virus 17D
  • Yellow fever virus 1899/81
  • Yellow fever virus isolate Angola/14FA/1971
  • Yellow fever virus isolate Ethiopia/Couma/1961
  • Yellow fever virus isolate Ivory Coast/1999
  • Yellow fever virus isolate Ivory Coast/85-82H/1982
  • Yellow fever virus isolate Uganda/A7094A4/1948
  • Yellow fever virus strain French neurotropic vaccine
  • Yellow fever virus strain Ghana/Asibi/1927
  • Yellow fever virus Trinidad/79A/1979

Unclassified Flavivirus
  • Aedes flavivirus
  • Batu Cave virus
  • Cacipacore virus
  • Cell fusing agent virus
• Chaoyang virus
  • Chimeric Tick-borne encephalitis virus/Dengue virus 4
  • Culex flavivirus
  • Flavivirus CbaAr4001
  • Flavivirus FSME
  • Flavivirus SST-2008
  • Gadgets Gully virus
  • Greek goat encephalitis virus
  • Jugra virus
  • Kadam virus
  • Kamiti River virus
  • Kedougou virus
  • Montana myotis leukoencephalitis virus
  • Ngoye virus
  • Nounane virus
  • Quang Binh virus
  • Russian Spring-Summer encephalitis virus
  • Sokoluk virus
  • Spanish sheep encephalitis virus
  • T’Ho virus
  • Tai forest virus B31
  • Tamana bat virus
  • Tick-borne flavivirus
  • Wang Thong virus
  • Flavivirus sp.

One of the most prominent members of the genus Flavivirus is the Yellow Fever Virus (YFV). This was the first human pathogenic virus isolated in 1927. Although a safe and efficient vaccine was produced in 1937, there are still more than 200,000 annual cases in Africa alone, and about 15% of the cases enter a critical phase with a chance of survival of about 50%. 
In more recent years, the Flavivirus genus gained further attention due to the increasing incidence of infections caused by the West Nile Virus (WNV) in America, and the Dengue Virus (DENV) in subtropical areas of the world. WNV, isolated in Uganda in 1937, is endemic in Africa and Southern Europe, but its appearance in America in 1999 was followed by a rapid geographic spread from Canada to Argentina in 2008, resulting in thousands of deaths and disabled patients. Similarly, the four DENV serotypes have considerably spread all over the world in recent years. With billions of persons at risk, more than 50 million cases and about 12,500 - 25,000 deaths per year, DENV is robustly emerging in a growing number of countries.

Additional clinically significant Flaviviruses are the Japanese Encephalitis Virus (JEV) and the Tick-Borne Encephalitis Virus (TBEV). Japanese encephalitis (JE) is the leading cause of viral encephalitis in Asia, with 30,000-50,000 cases reported annually. Case-fatality rates range from 0.3% to 60%, depending on the population and age. Rare outbreaks in the US territories in Western Pacific have occurred. Residents of rural areas in endemic locations are at highest risk, since this infection does not usually occur in urban areas. Countries which had major epidemics in the past, but which have controlled the disease primarily by vaccination, include China, Korea, Japan, Taiwan and Thailand. There is no specific treatment available for Japanese encephalitis.

Tick-borne encephalitis is a viral infection of the central nervous system affecting humans and many other mammals. Russia and Europe report between 10,000-12,000 human cases per year. There is no remedy for the disease, but the infection can be prevented by vaccination. In humans, the disease is lethal in approximately 1% of cases and leaves 10-20% of its survivors with permanent neurological damages.

The Murine Favivirus Modoc (MODV) was first isolated in 1958 from white-footed deer mice in Modoc County, California. This virus was subsequently recognized as a Flavivirus and phylogenetic analysis placed MODV in the classical NKV group. MODV is neuroinvasive with a pathology similar to flaviviral encephalitis in humans.
There are a number of environmental, demographic and ecological reasons to believe that either novel or known Flaviviruses will keep emerging. In this respect, the shining success of vaccination against YFV has been hampered by difficulties encountered when such programs were launched against DENV. In particular, the presence of four DENV serotypes has complicated vaccine design because incomplete protection against one serotype may influence the disease outcome once infection is established by a different serotype, through a process known as "antibody-mediated disease enhancement". Therefore, in addition to vaccine design efforts, there has been a growing interest in the discovery of antiviral drugs effective against Flaviviruses.

The optimal Flavivirus drug should preferably be active against all the four DENV serotypes and some other Flaviviruses, such as e.g. YFV, WNV, TBEV and JEV. Additionally, it should be suitable for oral administration and should possess high oral bioavailability.

Ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a broad-spectrum RNA virus replication inhibitor which, in combination with pegylated interferon, has proven to be effective against HCV infections. In an aerosol form, it is used for the treatment of paediatric respiratory syncytial virus (RSV) infections. Almost all of the RNA viruses as well as some DNA viruses are sensitive to the in vitro antiviral activity of ribavirin. However, Flaviviruses are much less sensitive to ribavirin than RSV. The effect of ribavirin was studied in rhesus monkeys infected with YFV or DENV type 1. Both therapeutic and prophylactic protocols were studied. However, no effect on viremia or survival was observed. Since the antiviral activity of ribavirin is based on a non-specific mechanism, the design of safe and more potent analogues of ribavirin is likely to be very difficult to achieve. EICAR, the 5-ethynyl analogue of ribavirin, was shown to be in vitro roughly 10- to 20-fold more potent in inhibiting Flavivirus replication. Such improved activity, however, corresponded to an increase in toxicity, which is explained by the fact that EICAR 5’-monophosphate is also more potent in inhibiting the IMP dehydrogenase.
Recently, a heterocyclic molecule with an in vitro anti-DENV activity was reported. Its mechanism of action is thought to be related to the inhibition of cellular IMP dehydrogenase.

In the light of the foregoing, a need still exists for an effective and specific anti-Flavivirus agent having reduced or no toxicity.

These and other needs are achieved by the present invention, which is based on the aforementioned finding that compounds belonging to the classes of avermectins and milbemycins, particularly the substance known as ivermectin, are capable of effectively inhibiting Flavivirus helicase, a viral enzyme required for the replication of Flaviviruses.

The present inventors have experimentally shown that ivermectin is specifically active against a number of viruses belonging to the genus Flavivirus, with an EC50 in the nM range, which is indicative of good antiviral activity. In particular, such EC50 value indicates that the active ingredient is effective at a concentration range in which ivermectin displays low toxicity and can therefore be safely used in animals and human beings, especially in view of previous studies suggesting that the molecule can be safely employed at doses up to 10 times the highest FDA-approved dose of 200 µg/kg (Guzzo CA et al. J. Clin. Pharmacol. 2002;42:1 122-33).

The inventors have further analyzed the effects of ivermectin on Flaviviruses in cell cultures, demonstrating that this drug is capable of dramatically inhibiting the replication of a number of clinically important Flaviviruses, such as the DENV, the JEV, the TBEV, for which no vaccine or effective inhibitor exists, as well as the YFV and the MODV.

The results obtained in a virus yield assay to assess viral RNA decrease by quantitative RT-PCR following ivermectin treatment, show that the EC50 of ivermectin is in the nanomolar range for DENV, JEV, TBEV, YFV and MODV.
Based on the structural similarity shared by the antiparasite macrolides belonging to the classes of avermectins and milbemycins, said helicase-inhibiting activity is envisaged to be highly conserved within such classes.

Thus, an aspect of the present invention is a substance selected from the group of avermectins and milbemycins as defined in the appended claims for use in the therapeutic treatment of a Flavivirus infection, as well as the use of a substance as defined above for preparing an antiviral medicament for the therapeutic treatment of a Flavivirus infection.

Prominent representatives of such classes of substances include, without limitation, ivermectin, avermectin, doramectin, selamectin, moxidectin, emamectin, eprinomectin, milbemectin, abamectin, milbemycin oxime, nemadectin and derivatives thereof, in a free form or in the form of a physiologically acceptable salt.

In a preferred embodiment of the invention, the substance is ivermectin. This drug is available on the market e.g. from Sigma Aldrich. Commercially-available ivermectin is a mixture of at least 80% avermectin B₁₄ and 20% or less of avermectin Bib.

Thus, according to a more preferred embodiment of the invention, the substance is a mixture of avermectin B₁₄ in an amount of 80% or more and avermectin B₁₁b in an amount of 20% or less. Even more preferably, the substance is avermectin B₁₄.

The use of ivermectin as a medicament in the present invention is particularly preferred in view of its effective inhibiting activity against the replication of a number of different Flavivirus species, and also in view of the fact that this drug is currently available on the market as a medicament authorized for oral administration. Thus, obtaining a marketing authorization for ivermectin as an antiviral medicament for oral administration will probably not require to perform phase 1 and phase 2 trials.

Furthermore, the inventors have found that ivermectin is specifically effective against the genus Flavivirus. As a matter of fact, no antiviral activity was observed either against other Flaviviridae viruses or against other virus families.
In view of the experimental studies carried out by the present inventors including, *inter alia*, the determination of the EC50 value as mentioned above, the antiviral medicament against Flavivirus infections is preferably provided as an oral pharmaceutical dosage form. Non limiting examples of pharmaceutical dosage forms suitable for oral administration are a pill, a tablet, a capsule, a liquid solution or suspension, a powder.

By way of example, a dose suitable for oral administration to a subject in need of an anti-Flaviviral treatment is comprised between about 50 to about 2000 μg/kg of body weight. Such a dose may be provided as a single administration or it can be divided in a plurality of administrations, e.g. 2 or 3 administrations.

Within the scope of the present description, the subject to be administered with avermectin or milbemycin according to the present invention is a mammal. This expression is intended to encompass any mammal, including *inter alia* a human being.

The following is a detailed description of the tests and studies carried out by the present inventors in order to demonstrate and characterize the antiviral activity of ivermectin. The following detailed description is provided by way of illustration only, with reference to the appended drawings wherein:

Figure 1 is a schematic representation of the crystal structure of the Kunjin virus NS3 helicase domain (Protein Data Bank entry 2QEY; Mastrangelo E et al. J. Mol. Biol. (2007) 372, 444^55). Domains I (in gray) and II (in black) are structurally similar, each of them being composed of six β-strands surrounded by four and three a-helices, respectively. Domain III (in light gray) is composed of five parallel a-helices and two antiparallel β-strands. The inventors modelled the position of a dsDNA (sticks) segment by superposition of KUNV NS3 residues 186-619 on the DNA-bound bacterial helicase PcrA (pdb: 3PJR). Helices a2, of domain II, and <x9, of domain III, forming the opposite sides at the entry crevice, are recalled in the figure.
Figure 2 shows the results of the in vitro inhibition assay carried out using Kokobera virus helicase domains. The two lanes on the left host the positive control (+Control) in the absence of enzyme and the negative control (-Control; heat-denatured duplex).

Figure 3 shows the results of the CPE reduction assay used to assess the anti-YFV activity of ivermectin.

Figure 4 shows the results of the virus yield assay used to assess the anti-DENV activity of ivermectin.

Figure 5 shows the results of the assay carried out to assess the anti-DENV activity in BHK cells containing Dengue subgenomic replicons.

Figure 6 shows the results of the virus yield assay carried out to assess the anti-MODV activity of ivermectin.

Figure 7 shows the results of the virus titration assay carried out to assess A) the Anti-JEV and B) the anti-TBEV activity of ivermectin.

The target-based design of inhibitors of flaviviral enzymes may be a promising strategy towards the development of selective inhibitors of Flavivirus replication.

The Flavivirus genome encodes a 370 kDa polyprotein precursor that is partly inserted into the membrane of the endoplasmic reticulum. Subsequently, the polyprotein is processed by cellular and viral proteases to yield three mature structural proteins (designated as C, M, and E, respectively), and seven non-structural proteins (designated as NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5, respectively). During replication, the viral genome is transcribed into a negative-strand RNA and used as template to synthesise the daughter viral genomic RNA. Many viral proteins are required for RNA replication. Some of the non-structural proteins are multi domain proteins endowed with more than one function. Besides the evident role of the RdRp (RNA-dependent RNA polymerase, the C-terminal domain of NS5) to maintain proper viral replication, the nascent transcript must be
unwound from its complementary template RNA. This is performed by the C-terminal domain of NS3 (the "helicase domain"). Then, the newly synthesized RNA must be properly capped (cap I structure) and this process requires three enzyme activities: a RNA triphosphatase activity (the C-terminal domain of NS3), a guanylyltransferase activity (likely the N-terminal domain of NS5) and a methyltransferase activity (MTase; the N-terminal domain of NS5). Therefore, NS3 (N-terminal protease and C-terminal helicase activity) and NS5 (N-terminal MTase and C-terminal RdRp) are the main actors of the viral replication in the context of a multiprotein complex, likely comprising proteins from the host cell too.

The inventors selected the C-terminal NS3 helicase domain of the genus Flavivirus as a valuable drug target. Compounds based on the structure of nucleoside-5'-triphosphates are an attractive tool for inhibition of the helicase activity. However, it is known that analogues of nucleoside-5'-triphosphates, with a modified base such as ribavirin-TP, IDA-TP or ITA-TP, when tested at ATP concentrations equal to the K_m values determined for the ATPase reaction of each of the viral enzymes, inhibit only weakly the ATPase reaction mediated by NTPase/helicases from HCV, JEV, DENV and WNV. Moreover, since many distinct mammalian metabolic enzymes require ATP as an energy source, an ATP-mimetic compound may turn out to be generally toxic.

A different helicase inhibitor search strategy should therefore, in principle, be directed to the inhibition of the enzyme's RNA handling mechanisms. For the search of inhibitors based on such a new conceptual scheme, the inventors targeted the helicase ssRNA access site. An in silico model of the helicase/RNA interaction was produced and used to identify a likely ssRNA access site to the enzyme active region (figure 1). The selected region was then explored in silico using compounds from the public LOPAC library (Sigma-Aldrich) of available low molecular weight compounds.

Based on the results obtained from the in silico studies, ivermectin was selected, together with a number of other molecules, for subsequent in vitro helicase activity inhibitory tests. The inventors surprisingly found that, amongst the group of candidate helicase inhibitors identified by the in silico studies, only ivermectin shows the expected activity.
The helicase inhibitory activity of ivermectin was demonstrated by in vitro assays carried out on the helicase domains of two different Flaviviruses: the Kunjin virus and the Kokobera virus. The Kunjin virus and Kokobera virus helicase domain were expressed and purified as described (Mastrangelo et al., Acta Cryst. (2006). F62, 876-879; De Colibus et al., Acta Cryst. (2007). F63, 193-195). Example 1 in the experimental section below discloses the production of the recombinant helicase domains in Escherichia coli.

The helicase inhibition activity was assessed using a radiolabeled RNA substrate in the presence of Mg\(^2+\) and ATP. The RNA substrate was prepared as described in Wu, J. et al. (2005) Structure of the Flavivirus helicase: implications for catalytic activity, protein interactions, and proteolytic processing. J. Virol. 79, 10268-10277. Example 2 discloses the helicase activity inhibition assays carried out on the helicase domains obtained according to Example 1.

Inhibition assays performed on infected cells showed a potent antiviral activity of ivermectin against YFV, DENV, JEV, TBEV and MODV. In particular, ivermectin was shown to possess an anti-YFV activity by both a CPE reduction assay (EC\(_{50}\) = 7.4 and 10.3 nM; figure 3) and a virus yield reduction assay (quantification by RT-PCR; EC\(_{50}\) = 4.9 nM).

The anti-DENV activity (EC\(_{50}\) = 710 +/- 350 nM) was demonstrated by a virus yield reduction assay (quantification by RT-PCR; figure 4). Ivermectin was also shown to possess anti-DENV activity in BHK cells containing Dengue subgenomic replicons (figure 5).

The effectiveness of ivermectin as an antiviral agent was also shown against the related Flavivirus MODV (EC\(_{50}\)=730 nM) by a virus yield reduction assay (quantification by RT-PCR) (figure 6).

Furthermore, in a virus yield assay carried out with Vero cells seeded on a 24-wells plate, an MOI of about 0.1-1, analysis of the cell culture supernatant 72 hours post infection, quantification of the antiviral activity by quantitative RT-PCR, the ivermectin EC\(_{50}\) values were of about 100-1000 nM for both JEV and TBEV. Part of each corresponding cell
supernatant was removed and stored at -80°C before viral titration on BHK21 cells (TCID50/ml). The viral titration on BHK21 cells showed that the ivermectin EC$_{50}$ values were 300 and 200 nM for JEV and TBEV, respectively (figure 7, A and B).

The selectivity of the antiviral activity of ivermectin against the genus Flavivirus was shown by its failure to inhibit Bovine viral diarreha virus (BVDV), which belongs to the genus Pestivirus of the family Flaviviridae. Effectively the ivermectin concentration required to achieve 50% protection of mock-infected MDBK (Bovine normal kidney) cells from the BVDV induced cytopathogenicity is about 1.5 µM as determined by the MTT method (ivermectin concentration required to reduce the viability of MDBK cells by 50% being 11 µM). Moreover ivermectin does not inhibit other viruses belonging to several other families such as Coxsackievirus B2 (CVB-2) and Poliovirus 1 (Sb-1; ss(+)-RNA virus; Picornaviridae family); Herpesvirus 1 (HSV-1; dsDNA virus; Herpesviridae family) and Vaccinia Virus (VV; dsDNA virus; Poxviridae family); Vesicular Stomatitis Virus (VSV; ss(-)-RNA virus; Rhabdoviridae family) and Respiratory Syncytial Virus (RSV; ss(-)RNA; Paramixoviridae family), for which the ivermectin concentration required to reduce the plaque number by 50% in mock-infected VERO-76 (Monkey normal kidney) monolayers is > 6 µM (ivermectin concentration required to reduce the viability of VERO 76 monolayers by 50% being 6 µM). Furthermore in the Reoviridae family (ss(+)-RNA virus) the ivermectin concentration required to achieve 50% protection of mock-infected BHK cells (Hamster normal kidney fibroblast) from the Reovirus-1 (Reo-1) induced cytopathogenicity, is >1.5 µM (ivermectin concentration required to reduce the viability of BHK monolayers by 50%, being 1.5 µM).

Example 1: production of the complete helicase domains
Briefly, PCR products were obtained that include the complete helicase domains. They were re-amplified using GATEWAY-modified designed to encode N-terminal (His)$_6$-tagged recombinant proteins spanning amino acids 186-620 of the Kunjin NS3 gene and 189-620 of the Kokobera NS3 gene. Each of these products were subsequently cloned into pDEST 14 HN expression vector and the Kunjin and Kokobera constructs were transformed respectively into Escherichia coli Rosetta (DE3) pRos and C41 (DE3) pRos strains and the cells were grown in SB at 17°C and 2YT medium at 20°C respectively.
After the induction with 0.5 mM isopropyl β-D-thiogalactopyranoside (IPTG), the cells were grown for 16 hours and harvested by centrifugation then lysed in the lysis buffer by sonication. After the centrifugation at 23,000 g for 1 h, the supernatants were loaded on a metal affinity HisTrap HP column; recombinant helicase domains, eluted at 250 mM imidazole, were subsequently loaded onto an HiLoad 16/60 Superdex 200 column. Kunjin virus helicase domain was eluted using NaCl 100 mM, DTT 1 mM, Bicine 10 mM pH 8.5, and concentrated to 4 mg ml$^{-1}$. Kokobera helicase domain was eluted using 10 mM imidazole, 300 mM NaCl pH 8.0 and concentrated to 14 mg ml$^{-1}$.

**Example 2: helicase activity inhibition assays**

Briefly, primer 1 (5’-CACCUCUCUGAGUCGACCUGCAGGCAUGC-3’, SEQ ID NO:1) was labelled at its 5’ end with T4 polynucleotide kinase and [³²P]ATP, and annealed with the complementary primer 2 (5’-CGACUCUGAGAGGUGG-3’ SEQ ID NO:2). The helicase domains (200 nM each) were pre-incubated with an amount of ivermectin (Sigma Aldrich, cat. no. 18898) comprised between 50 and 400 nM. The reactions were initiated by the addition of the proteins to the reaction mixture containing 6 fmol of RNA and were quenched after 30 min at 37 °C by the addition of 6 μl of loading dye (50 mM EDTA, 0.5% SDS, 50% glycerol, 0.1% Bromophenol Blue). The assay mixtures were subjected to electrophoresis on non-denaturing 17% polyacrylamide gels that were dried and analyzed by phosphoimage (Typhoon, GE-Healthcare). The gels showed that ivermectin is able to inhibit the activity of the two helicase domains at a concentration ranging between 50 and 100 nM (figure 2).

**Example 3: antiviral assay**

To each well of a 96-well plate 100 μl of culture medium containing 100 CCID$_{50}$ (i.e. 50% cell culture infectious dose) of virus was added to each well after which two-fold serial dilutions of the compounds and 100 μl cell suspension (2.5 * 10$^4$ Vero-B) was added. After a one-week incubation, culture medium was discarded and cell metabolic activity was quantified using the ATP-Lite method. The percentage cytopathic effect (CPE) was calculated as follows: %CPE = 100 × ((OD$_{virus+compound}$ - OD$_{x,c}$/))/(OD$_{CC}$ - OD$_{vc}$)). In this formula, OD$_{cc}$ represents the optical density of the uninfected untreated cells, whereas OD$_{vc}$ and OD$_{vi}$$_{drug+compound}$ represent the optical densities of infected, untreated cells and
virus-infected cells that were treated with a given concentration of compound, respectively. The 50% effective concentration (EC50), which is defined as the compound concentration that is required to inhibit virus-induced CPE by 50%, was determined using logarithmic interpolation. Ribavirin was included as a reference compound.

**Viruses**

Modoc (MODV) strain M544 [American Type Culture Collection (ATCC) VR415] was propagated in BHK-21 cells. Yellow fever virus (YFV) 17D vaccine strain (Stamaril) [Aventis Pasteur (MSD, Brussels, Belgium)] was passaged once in Vero-B cells to prepare a working virus stock and stored at -80 °C until further use. Dengue virus (DENV) serotype 2 New Guinea C (NGC) strain was cultivated in either Vero-B or C6/36 mosquito cells.

**Cytotoxic and cytostatic assay in Vero-B cells**

Potential cytotoxic effects of the compounds were evaluated in uninfected quiescent Vero-B cells. The cells were seeded at $1 \times 10^4$ cells/well in a 96-well plate in the presence of two-fold serial dilutions and incubated for one week. After one week, the culture medium was discarded and 100 µl 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium/phenazinemethosulfate (MTS/PMS; Promega, Leiden, The Netherlands) in PBS were added to each well. Following a 2-hour incubation at 37 °C, the optical density was determined at 498 nm. The cytotoxic activity was calculated using the following formula: 

$$\%\ CPE = 100 \times \frac{OD_{\text{compound}}}{OD_{\text{c,e}}}$$

where $OD_{\text{compound}}$ and $OD_{\text{c,e}}$ are the optical density at 498 nm of the uninfected cell cultures treated with the compound and of the uninfected, untreated cell cultures, respectively. The 50% cytotoxic concentration (i.e., the concentration that reduces the total cell number with 50%; CC50) was calculated by linear interpolation.

The screening was performed onto Vero cells grown in 24-well tissue culture plates. The virus infection was obtained using either the JEV strain SA-14 (GenBank accession number U14163) and the TBEV strain Oshima 5-10 (GenBank accession number AB062063). Viral strains were used at a dilution of MOI < 1, (i.e. between 0.1 and 1).
Ivermectin was used at a final concentration ranging between 0 and 10 µM. A pre-incubation in the presence of the antiviral was performed during the 90-minute virus adsorption step. Briefly, when Vero cells reached 90% confluence, the cell supernatant was removed and replaced by 100 µl of a medium mixture containing the virus and the antiviral compound at the targeted concentration (10, 5, 2.5, 1.25, 0.6, 0.3, 0.15 and 0 µM). After 1 h 30 at 37°C, the cells were washed once with 400 µl PBS. Subsequently, 1 ml of fresh complete medium plus antiviral compound at the targeted concentration (10, 5, 2.5, 1.25, 0.6, 0.3, 0.15 and 0 µM) was added in each wells and the plates were incubated for 72 h at 37°C, under 5% CO2 until analysis. All conditions were assayed in duplicate. 72 hours-post-infection, each corresponding cell culture supernatant was removed, clarified by centrifugation and stored at -80°C before analysis using a viral titer reduction assay.

The viral titer reduction assay was performed using BHK21 cells seeded in 96-well plates. When the cells reach 80% confluence, they were infected with 150 µl of ten-fold serial dilutions of the virus (targeted Vero cell clarified supernatants) for 4 days before microscopic examination and positive ECP well counting. For each supernatant sample, the infectivity titer was expressed as TCID50/ml using the Karber formulae. For each virus, titers of viral supernatants were then compared and represented as % of positive control (viral titer from infected cell supernatant sample without antiviral compound) for the calculation of IC50 values.

The results provided by the viral titer reduction assay are as follows: EC₈₀ = 0.3 µM for JEV and EC₅₀ = 0.2 µM for TBEV (see figure 7). The results were secondarily confirmed using a virus yield reduction assay (quantification by RT-PCR, data not shown).
1. A substance selected from the group consisting of ivermectin, avermectin, doramectin, selamectin, moxidectin, emamectin, eprinomectin, milbemectin, abamectin, milbemycin oxime, nemadectin and the macrolide derivatives thereof lacking the sugar residue attached at the C-13 position, in a free form or in the form of a physiologically acceptable salt, for use in the treatment of a Flavivirus infection.

2. A substance according to claim 1, which is ivermectin.

3. A substance according to claim 2, which is a mixture of avermectin B\textsubscript{1a} in an amount of 80% or more and avermectin B\textsubscript{1b} in an amount of 20% or less.

4. A substance according to claim 1, which is avermectin B\textsubscript{1a}.

5. A substance according to any of claims 1 to 4, wherein the Flavivirus is selected from the group consisting of YFV (yellow fever virus), DENV (Dengue virus), JEV (Japanese encephalitis virus), TBEV (tick-borne encephalitis virus) and MODV (Modoc virus).

6. A substance according to any of claims 1 to 5, which is a form suitable for oral administration.

7. The use of a substance selected from the group consisting of ivermectin, avermectin, doramectin, selamectin, moxidectin, emamectin, eprinomectin, milbemectin, abamectin, milbemycin oxime, nemadectin and the macrolide derivatives thereof lacking the sugar residue attached at the C-13 position, in a free form or in the form of a physiologically acceptable salt, for preparing an antiviral medicament for the therapeutic treatment of a Flavivirus infection.

8. The use according to claim 7, wherein the substance is ivermectin.
9. The use according to claim 8, wherein the substance is a mixture of avermectin B$_{1a}$ in an amount of 80% or more and avermectin B$_{1b}$ in an amount of 20% or less.

10. The use according to claim 9, wherein the substance is avermectin B$_{1a}$.

11. The use according to any of claims 7 to 10, wherein the Flavivirus is selected from the group consisting of YFV (yellow fever virus), DENV (Dengue virus), JEV (Japanese encephalitis virus), TBEV (tick-borne encephalitis virus) and MODV (Modoc virus).

12. The use according to any of claims 7 to 11, wherein the medicament is in a form suitable for oral administration.

13. The use according to claim 12, wherein the medicament is in a form suitable for administering a dose of the substance comprised between 50 a 2000 µg/kg of body weight, either in a single dose or in a plurality of divided doses.

14. A method for treating a Flavovirus infection in a patient, the method comprising:
   administering to said patient a therapeutically effective amount of a substance selected from the group consisting of ivermectin, avermectin, doramectin, selamectin, moxidectin, emamectin, eprinomectin, milbemectin, abamectin, milbemycin oxime, nemadectin and the macrolide derivatives thereof lacking the sugar residue attached at the C-13 position, in a free form or in the form of a physiologically acceptable salt.

15. The method according to claim 14, wherein the Flavivirus is selected from the group consisting of YFV (yellow fever virus), DENV (Dengue virus), JEV (Japanese encephalitis virus), TBEV (tick-borne encephalitis virus) and MODV (Modoc virus).

16. The method according to claim 15, wherein the substance is ivermectin.

17. The method according to claim 15, wherein the substance is a mixture of avermectin B$_{1a}$ in an amount of 80% or more and avermectin B$_{1b}$ in an amount of 20% or less.
18. The method according to claim 15, wherein the substance is avermectin Bi₉₆.

19. The method according to any of claims 14 to 18, wherein the medicament is in a form suitable for oral administration.

20. The method according to claim 19, wherein the medicament is in a form suitable for administering a dose of the substance comprised between 50 and 2000 µg/kg of body weight, either in a single dose or in a plurality of divided doses.
$CC_{50} = 3.81 \pm 0.25 \mu M$
$EC_{50} = 0.71 \pm 0.35 \mu M$

Figure 4
Figure 5
Murine flavivirus Modoc

![Graph showing % Cell metabolism and % Cell protection over varying concentrations of a compound.]

CC50 = 3.50 μM
EC50 = 0.73 μM

Figure 6
A

EC50 JEV = 0.3 µM

B

EC50 TBEV = 0.2 µM

Figure 7
INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2010/065880

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K31/7048 A61K31/366 A61P31/14
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>GB 1 390 336 A (SANKYO CO) 9 April 1975 (1975-04-09) cited in the application * abstract</td>
<td>1-15</td>
</tr>
</tbody>
</table>

[X] Further documents are listed in the continuation of Box C.  [X] See patent family annex.

* Special categories of cited documents:
  "A" document defining the general state of the art which is not considered to be of particular relevance
  "E" earlier document but published on or after the international filing date
  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  "O" document referring to an oral disclosure, use, exhibition or other means
  "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

Date of the actual completion of the international search
9 December 2010

Date of mailing of the international search report
15/12/2010

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer
Langer, Oliver
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>EP 0 170 006 A2 (AMERICAN CYANAMID CO [US]) 5 February 1986 (1986-02-05) cited in the application page 1, paragraph 1</td>
<td>1-15</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>GB 1390336 A</td>
<td>09-04-1975</td>
<td>AU 5663173 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CH 585789 A5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CH 585514 A5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE :2329486 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 415591 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FR 2187778 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL 42401 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IT 986430 B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 49014624 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SU 588926 A3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SU 1360574 A3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 7303857 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 615620 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 5984990 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2021894 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69005935 D1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69005935 T2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 0410615 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2062378 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FI 94262 B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 57832 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IE 902694 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL 95133 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 1958352 C</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 3068581 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 6092414 B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 903312 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 234644 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 94805 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5073567 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 9005842 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 1339965 C</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 68928606 D1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 68928606 T2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 86589 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2113340 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 1272588 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 1967325 C</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 6099437 B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 89806 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 63057591 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 4328385 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 3519834 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 51991 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 53591 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 53691 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 248885 A</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>ES 8703159 A1</td>
<td>16-04-1987</td>
<td></td>
</tr>
<tr>
<td>HU 43637 A2</td>
<td>30-11-1987</td>
<td></td>
</tr>
<tr>
<td>IE 58100 B1</td>
<td>30-06-1993</td>
<td></td>
</tr>
<tr>
<td>JP 2524688 B2</td>
<td>14-08-1996</td>
<td></td>
</tr>
<tr>
<td>JP 7233170 A</td>
<td>05-09-1995</td>
<td></td>
</tr>
<tr>
<td>JP 2039369 C</td>
<td>28-03-1996</td>
<td></td>
</tr>
<tr>
<td>JP 7076223 B</td>
<td>16-08-1995</td>
<td></td>
</tr>
<tr>
<td>JP 61010589 A</td>
<td>18-01-1986</td>
<td></td>
</tr>
<tr>
<td>PT 80577 A</td>
<td>01-07-1985</td>
<td></td>
</tr>
<tr>
<td>WO 2009032975 A1</td>
<td>12-03-2009</td>
<td></td>
</tr>
<tr>
<td>AU 2008296215 A1</td>
<td>12-03-2009</td>
<td></td>
</tr>
<tr>
<td>CA 2701465 A1</td>
<td>12-03-2009</td>
<td></td>
</tr>
<tr>
<td>EP 2200428 A1</td>
<td>30-06-2010</td>
<td></td>
</tr>
<tr>
<td>KR 20100080790 A</td>
<td>12-07-2010</td>
<td></td>
</tr>
<tr>
<td>US 2010247485 A1</td>
<td>30-09-2010</td>
<td></td>
</tr>
</tbody>
</table>
1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
   a. (means)
      - [X] on paper
      - [X] in electronic form
   b. (time)
      - [X] in the international application as filed
      - [X] together with the international application in electronic form
      - [ ] subsequently to this Authority for the purpose of search

2. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments: